We are pleased to announce that our VPM1002 trial, where VPM1002 was given as a prophylaxis against severe respiratory infectious diseases including COVID-19 in the elderly, has successfully been published in the journal Clinical Infectious Diseases. We could show that VPM1002 compared to placebo is reducing the days with severe respiratory disease. Read more!